The Brazilian Orthopaedic Journal (RBO) has been included in PubMed, after a long and difficult selection process.
Several recognitions must be given regarding this victory of our journal in the publishing field and thus, let us just enumerate them without order of importance.
-to our publisher, Elsevier and its international structure, which had great participation in the process, by publishing our works according to PubMed standards and guiding us throughout the requirements; -to our authors, who, by submitting increasingly betterquality works, increased the journal's level and made its selection possible; -to our editors, who selected and guided the drafting of the works; -and to all individuals directly linked to RBO production.
The Brazilian Orthopedics professionals would like to thank all of you.
Initially, studies published in 2014 and 2015 are already indexed and available, but the current board authorized the investment required to index all studies published from 2009 to 2013 and thus, complete the collection of publications from recent years.
To date, our position regarding the editorial board was to construct a journal that depicted Brazilian orthopedics. In some situations, we published studies which, although did not have very high quality, depicted our reality. At other times, we returned papers several times, until the author improved the manuscript, as we believed that author was a promising one, or that a group represented an important regional reality.
When the indexing was accomplished, we analyzed the rights we have acquired and found that, without doubt, the internationalization of Brazilian orthopedics was the main gain.
Our studies will be available to be read, consulted and appraised worldwide.
We have great concerns about this appraisal, as our studies have never been presented so openly before.
Thanks to globalization, we will receive studies from around the world, which will compete with ours in the appraisal process to be published in RBO.
We currently have great difficulty to circulate our domestic production, having a delay of almost one year. How will the influx of more studies occur?
We have a space limitation that is considered adequate by our publisher. This limitation is not economical, but technical, as it establishes a size for RBO that is compatible with its scientific production.
An example of globalization occurred with the Clinics journal, published by Hospital das Clínicas da FMUSP, which now receives 35% of Chinese and 20% of Turkish studies, compared to 35% of Brazilian studies.
In this first month of indexing, we received a very wellstructured Iranian study, on the incidence of vitamin D measurement decrease in the Iranian population. How should we proceed -should we publish this study, instead of one carried out in Brazil?
Together with the rights, we have to deal with the obligations, as we have to position ourselves in a similar way as all the journals that are at the same level we have reached.
That means to regulate the number of authors, limit citations to a more recent period, avoid case reports, and favor original studies; in short, to follow a stricter and less patronizing editorial line.
We currently have a 35% rejection rate on average and, aiming to avoid publication delay and to position ourselves as other orthopedic journals do in PubMed, we must soon reach 50% of rejection.
After 50 years of life, RBO reaches a maturity that will not be mild, or serene, as it will require several adjustment measures.
These necessary changes will result in a new RBO format. As the editor, I do not intend to stray from the philosophy of maintaining a journal that portrays the Brazilian orthopedic field.
